Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diane Seimetz

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Journal of Cancer|July 1, 2011
Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab)Diane Seimetz
Clinical and Translational Medicine|October 23, 2019
From fiction to science: clinical potentials and regulatory considerations of gene editingMaria Schacker, Diane Seimetz
Therapeutic Innovation & Regulatory Science|June 14, 2018
Expediting Drug Development: FDA's New Regenerative Medicine Advanced Therapy DesignationAnnegret Vaggelas, Diane Seimetz
Cell Medicine|July 8, 2020
Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs?Diane Seimetz, Karl Heller, Jan Richter
Cancer Treatment Reviews|March 30, 2010
Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapyDiane Seimetz, Horst Lindhofer, Carsten Bokemeyer
Mabs|March 2, 2010
Catumaxomab: clinical development and future directionsRolf Linke, Anke Klein, Diane Seimetz
Biomarker Insights|December 21, 2020
Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory LandscapeMariya Gromova, Annegret Vaggelas, Gabriele Dallmann, et al.
Expert Opinion on Drug Safety|March 13, 2020
19th Annual Meeting of the Safety Pharmacology Society: regulatory and safety perspectives for advanced therapy medicinal products (cellular and gene therapy products)Icilio Cavero, Diane Seimetz, David Koziel, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 4, 2012
Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivoKirsten Dettmar, Isabell Seitz-Merwald, Carsten Lindemann, et al.
International Journal of Cancer|June 25, 2011
Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascitesMarion G Ott, Frederik Marmé, Gerhard Moldenhauer, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Journal of Cancer|July 1, 2011
Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab)Diane Seimetz
Clinical and Translational Medicine|October 23, 2019
From fiction to science: clinical potentials and regulatory considerations of gene editingMaria Schacker, Diane Seimetz
Therapeutic Innovation & Regulatory Science|June 14, 2018
Expediting Drug Development: FDA's New Regenerative Medicine Advanced Therapy DesignationAnnegret Vaggelas, Diane Seimetz
Cell Medicine|July 8, 2020
Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs?Diane Seimetz, Karl Heller, Jan Richter
Cancer Treatment Reviews|March 30, 2010
Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapyDiane Seimetz, Horst Lindhofer, Carsten Bokemeyer
Mabs|March 2, 2010
Catumaxomab: clinical development and future directionsRolf Linke, Anke Klein, Diane Seimetz
Biomarker Insights|December 21, 2020
Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory LandscapeMariya Gromova, Annegret Vaggelas, Gabriele Dallmann, et al.
Expert Opinion on Drug Safety|March 13, 2020
19th Annual Meeting of the Safety Pharmacology Society: regulatory and safety perspectives for advanced therapy medicinal products (cellular and gene therapy products)Icilio Cavero, Diane Seimetz, David Koziel, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 4, 2012
Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivoKirsten Dettmar, Isabell Seitz-Merwald, Carsten Lindemann, et al.
International Journal of Cancer|June 25, 2011
Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascitesMarion G Ott, Frederik Marmé, Gerhard Moldenhauer, et al.
Pageof 2